Drug intelligence / Profile preview

CF018

Development stage: Preclinical
Lead developer: CF PharmTech
Administration: Inhalation

Overview

CF018 is a drug developed by CF PharmTech, a Chinese specialty pharmaceutical company focused on respiratory drugs. It is likely an inhalation product intended for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, respiratory infection, pulmonary fibrosis, and pulmonary hypertension.

Beyond the preview

Go deeper on CF018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF018.

Explore the full profile